Retatrutide
Triple-action peptide with 24% average weight loss in trials.
Read the full profileHead-to-head reference
RetatrutideversusTirzepatide
Retatrutide is the newer, multi-receptor GLP-1 — here's how it compares with tirzepatide on mechanism, dosing, and what the early research suggests.
Profile dataSide-by-side fieldsReviewed July 13, 2026
01Short answer
Retatrutide and Tirzepatide are different compounds.
This guide compares the same profile fields for both. It does not decide which is better, recommend either compound, or determine whether switching or combining them is appropriate.
02
Specimen cards
Meet the two profiles
Tirzepatide
FDA-approved for weight loss. Patients lose 20%+ of their body weight.
Read the full profile03
Field notes
Compare them side by side
Profile fieldARetatrutideBTirzepatide
Overview
Retatrutide is a triple-action peptide that tells your body to eat less, burn more calories through glucagon, and improve blood sugar control, all in one molecule for powerful weight and metabolic effects.
Tirzepatide is a dual peptide that mimics GLP-1 and GIP to powerfully suppress appetite, slow digestion, and improve insulin sensitivity, helping many people lose significant weight and control blood sugar.
Safety
Grade C · Moderate Safety
Still in clinical trials. GI side effects are common but manageable.
Investigational drug, not yet approved. Titrate slowly to minimize side effects. Do not mix in the same syringe as other peptides. Inject GLP-1s on their own.
Grade A · Excellent Safety
FDA-approved with extensive clinical trial data. Well-characterized side effect profile.
Common GI side effects typically improve over 4-8 weeks. Titrate slowly to minimize nausea. Not for Type 1 diabetes. Do not mix in the same syringe as other peptides. Inject GLP-1s on their own.
Profile dosing context
Start at 0.5 mg weekly, titrate to 2.5-5 mg weekly
weekly
12 weeks on, 12 weeks off (per clinical trials)
Slow titration is key. Increase dose every 4 weeks to minimize GI effects
2.5 mg weekly, titrating up every 4 weeks
weekly
12-24 weeks per treatment cycle
Start at 2.5 mg and increase slowly (every 4 weeks) to minimize GI side effects. Take at the same time each week.
Requires titration
Yes
Yes
Occasional side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site irritation
- Nausea
- Vomiting
- Diarrhea
- Reduced appetite
- Constipation
- Indigestion
- Injection site reactions
Same fields. No invented certainty.
The comparison pulls from the live peptide profiles used across The Peptide App. Use it to spot differences in documented context, titration notes, and safety flags. Missing data remains missing rather than being inferred.
- Retatrutide
- Triple-action peptide with 24% average weight loss in trials.
- Tirzepatide
- FDA-approved for weight loss. Patients lose 20%+ of their body weight.
Useful context, without a protocol.
What's the difference between Retatrutide and Tirzepatide?
Retatrutide and Tirzepatide are distinct compounds and can differ in mechanism, documented profile context, titration notes, evidence, and safety flags. The comparison table shows the same stored fields side by side and leaves unavailable information blank.
Is Retatrutide or Tirzepatide better?
There is no universal answer, and this page does not rank or recommend either compound. A licensed professional can interpret the evidence, product status, and individual context; this page is only a structured research comparison.
Can you take Retatrutide and Tirzepatide together?
Combining peptides can change dosing complexity and risk. This comparison is not medical advice, and it should not be used to start, stop, or combine protocols. A licensed professional is the right person to evaluate whether any combination is appropriate.
This comparison is for research and educational purposes. It does not diagnose, treat, prescribe, or replace guidance from a licensed professional. Always follow the instructions provided with your product.
From research to routine
Open the appTrack either protocol with less guesswork.
Keep dose timing, reminders, and protocol notes together in The Peptide App.